fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Journal of the American Academy of Dermatology publishes Zorvye (roflumilast) foam, 0.3% results for seborrheic dermatitis from pivotal phase III trial – Arcutis Biotherapeutics Inc

Written by | 7 Feb 2024

Arcutis Biotherapeutics, Inc. announced that the Journal of American Academy of Dermatology (JAAD) published positive results from the pivotal Phase III STRATUM trial evaluating Zoryve (roflumilast) foam, 0.3%… read more.

FDA approves Zoryve (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis – Arcutis Biotherapeutics

Written by | 19 Dec 2023

Arcutis Biotherapeutics, Inc. announced the FDA has approved the new drug application (NDA) for Zoryve (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in individuals 9… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.